XPhyto Therapeutics has engaged Stephen Schroeder with the design, renovation, and commissioning of plant in Bavaria with licence to extract up to 70 strains
Photo for illustration purposes only
XPhyto Therapeutics has entered into an exclusive two-year European consulting agreement with Canadian cannabis expert Stephen Schroeder to work on the design, renovation, and commissioning of XPhyto’s state-of-the-art hydroponics and extraction facility in Germany.
A science-based cannabis company, XPhyto is headquartered in Vancouver, Canada, and it is focused on formulation, clinical validation, and emerging European markets. Its German subsidiary, Bunker Pflanzenextrakte GmbH, holds a cannabis cultivation and extraction licence for scientific purposes granted by the German Federal Institute for Drugs and Medical Devices (BfArM) in July 2019.
Under the licence, Bunker is authorised to cultivate and extract up to 70 strains of Cannabis sativa and Cannabis indica for scientific purposes at its site in Bavaria.
Schroeder is an accomplished cannabis expert whose recent work includes several high-profile contracts. He was behind the design, construction and operation of one of the largest greenhouse and outdoor cannabis cultivation, extraction and isolation systems in the world, with scalability up to 100,000 hectares, based in Colombia, South America.
Schroeder also worked on the final design and optimisation of one of the largest premium hydroponics facilities in Canada.
“XPhyto is extremely pleased with the engagement," said Hugh Rogers, CEO of XPhyto. "Product quality is our primary objective, and Stephen and his team bring a set of skills and pride of craftsmanship that is aligned with our corporate vision" he added.
For Rogers, Schroeder’s extensive international network provides access to industry-leading system design, equipment, training, operational support and cannabis genetics. “This will be an essential component of the best-in-class cultivation and extraction operations we are building in Bavaria,” he said.
Xphyto has also announced it has signed an agreement to acquire Vektor Pharma, a German narcotics manufacturer, to acquire 100% of the issued and outstanding shares. XPhyto has also entered into an equipment purchase agreement with an affiliated company to purchase thin film drug delivery manufacturing equipment.